ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sinopharm, Bavarian Nordic and BioNTech side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Sinopharm×Bavarian Nordic×BioNTech×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

SinopharmBavarian NordicBioNTech
studies on the registry9558125
open to participants now18233
phase 3 studies under way739
reach primary completion within a year5211
programswith a study of their own in two years12424

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSinopharmBavarian NordicBioNTech
Phase 150%

Bavarian Nordic: 1 of its 4 programs at phase 1

  1. MVA-BN-EBVphase 1
25%

BioNTech: 4 of its 24 programs at phase 1

  1. BNT168phase 1
  2. BNT3219phase 1
  3. BNT351phase 1
  4. CV09070101phase 1
17%
Phase 250%

Bavarian Nordic: 1 of its 4 programs at phase 2

  1. MVA-BN-WEVphase 2
25%
67%
Phase 300%

Bavarian Nordic: 1 of its 4 programs at phase 3

  1. CHIKV VLP vaccinephase 3
25%

BioNTech: 3 of its 24 programs at phase 3

  1. pumitamigphase 3
  2. Elfetabart Drozuntecanphase 3
  3. trastuzumab pamirtecanphase 3
13%
Approved, new studies00%

Bavarian Nordic: 1 of its 4 programs at approved, new studies

  1. MVA-BN smallpox vaccineapproved, new study
25%

BioNTech: 1 of its 24 programs at approved, new studies

  1. BNT162 Vaccineapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sinopharm2 readouts · 0 phase 3···

Sinopharm, Feb ’27: 1 program whose next study reaches primary completion

  1. MVA-SIBP low dosephase 2 · Feb 28 · NCT07253675

Sinopharm, Mar ’27: 1 program whose next study reaches primary completion

  1. SIBP-A16 injectionphase 2 · Mar 31 · NCT07363837
·······
Bavarian Nordic2 readouts · 0 phase 3

Bavarian Nordic, Nov ’26: 1 program whose next study reaches primary completion

  1. MVA-BN smallpox vaccineapproved, new study · Nov 30 · NCT07199569
··

Bavarian Nordic, Feb ’27: 1 program whose next study reaches primary completion

  1. MVA-BN-WEVphase 2 · Feb 0 · NCT06899802
········
BioNTech4 readouts · 1 phase 3

BioNTech, Nov ’26: 1 program whose next study reaches primary completion

  1. BNT351phase 1 · Nov 0 · NCT07392372
·

BioNTech, Jan ’27: 1 program whose next study reaches primary completion

  1. pumitamigphase 3 · Jan 1 · NCT05879055
··

BioNTech, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. BNT162 Vaccineapproved, new study · Apr 12 · NCT07798648
·

BioNTech, Jun ’27: 1 program whose next study reaches primary completion

  1. BNT166Aphase 2 · Jun 0 · NCT07379580
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sinopharm

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Bavarian Nordic

New programs 1

  • MVA-BN-EBVphase 1 · first study · Oct 15 · Epstein-Barr Virus Infections

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

BioNTech

New programs 3

  • BNT3211phase 2 · first study · Nov 16
  • BNT3219phase 1 · first study · Oct 19
  • BNT3210phase 2 · first study · Oct 15

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.

ConditionSinopharmBavarian NordicBioNTech
Mpox, Monkeypoxall three · compare here

Bavarian Nordic in Mpox, Monkeypox: 1 program

  1. MVA-BN smallpox vaccineapproved, new study

Their studies: Bavarian Nordic’s studies of Mpox, Monkeypox in search

BioNTech in Mpox, Monkeypox: 1 program

  1. BNT166Aphase 2

Their studies: BioNTech’s studies of Mpox, Monkeypox in search

Influenza, Human2 of 3 · compare here

Sinopharm in Influenza, Human: 1 program

  1. Influenza virus split vaccine (0.7mL/vial)phase 2

Their studies: Sinopharm’s studies of Influenza, Human in search

–
Smallpox2 of 3 · compare here

Sinopharm in Smallpox: 1 program

  1. BSY001phase 1

Their studies: Sinopharm’s studies of Smallpox in search

Bavarian Nordic in Smallpox: 1 program

  1. MVA-BN smallpox vaccineapproved, new study

Their studies: Bavarian Nordic’s studies of Smallpox in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Sinopharm 3 of 12 · Bavarian Nordic 2 of 4 · BioNTech 11 of 24 programs (6 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.